10-Q · May 11, 2026
Aura Biosciences, Inc. reported its Q4 2026 results, marking continued financial strain with a net loss of $33.7 million, reflecting an increase from $27.5 million a year prior. Despite these losses, the company has…
Earnings analysis · 10-Q
AURA earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The provided 10-Q text does not include quarterly income statement, balance sheet or cash flow results, so revenue, margins, EPS, free cash flow and segment trends cannot be assessed. The filing reiterates an expected…
Read full summary
The provided 10-Q text does not include quarterly income statement, balance sheet or cash flow results, so revenue, margins, EPS, free cash flow and segment trends cannot be assessed. The filing reiterates an expected cash runway into the first half of 2029 and confirms completion of Phase 3 enrollment, but topline data are not expected until the second half of 2027. Financial pressure remains significant, with six-month net loss rising to $79.3 million from $54.5 million year over year and accumulated deficit reaching $559.7 million.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Cash runway into 1H 2029
Management states that existing cash, cash equivalents and marketable securities are sufficient to fund operations into the first half of 2029.
-
Phase 3 enrollment completed
The company completed enrollment in its global Phase 3 trial of bel-sar and expects topline data in the second half of 2027.
-
Disclosure controls deemed effective
As of June 30, 2026, management concluded that disclosure controls and procedures were effective, and reported no material changes in internal control over financial reporting during the quarter.
What to watch
-
Losses continue to expand
Net loss increased to $79.3 million for the six months ended June 30, 2026, from $54.5 million in the comparable 2025 period, an increase of $24.8 million or approximately 45.5%. Accumulated deficit reached $559.7 million as of June 30, 2026.
-
Long wait for pivotal data
Although enrollment is complete, management does not expect topline Phase 3 data until the second half of 2027; final results could be negative, inconclusive or insufficient to support approval.
-
20% workforce reduction
The company approved an organizational streamlining plan in August 2026 focused on ocular oncology, including an approximately 20% workforce reduction. Management warns that the reductions could result in loss of institutional knowledge and reallocation of responsibilities.
Management's outlook
The provided filing text does not include quantitative revenue or EPS guidance. Management states that existing cash, cash equivalents and marketable securities are expected to fund operations into the first half of 2029; formal outlook was not provided.
Earlier filings 4
10-K · March 30, 2026
Aura Biosciences is a clinical‑stage biotech focused on belzupacap sarotalocan (bel‑sar), a virus‑like drug conjugate (VDC) being advanced as a vision‑sparing therapy in ocular oncology and in bladder cancer (NMIBC).…
10-Q · November 13, 2025
Aura reported Q3 2025 net loss of $26,130,000 (diluted EPS $(0.40)), versus $21,042,000 (EPS $(0.42)) in Q3 2024; operating expenses rose to $27,906,000 from $23,232,000. The company strengthened its liquidity via a…
10-Q · August 13, 2025
Aura Biosciences reported a net loss of $27.019 million in Q2 2025, resulting in an EPS of -$0.47, slightly improving from -$0.41 in Q2 2024. Key highlights include a strong increase in cash and equivalents to $107.367…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.